SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec zooms on receiving Manufacturing Authorization for 22 medicinal products

17 Oct 2017 Evaluate

Panacea Biotec is currently trading at Rs. 252.00, up by 26.70 points or 11.85% from its previous closing of Rs. 225.30 on the BSE.

The scrip opened at Rs. 226.00 and has touched a high and low of Rs. 253.05 and Rs. 223.85 respectively. So far 76397 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 265.55 on 12-Sep-2017 and a 52 week low of Rs. 103.00 on 21-Nov-2016.

Last one week high and low of the scrip stood at Rs. 253.05 and Rs. 211.00 respectively. The current market cap of the company is Rs. 1385.80 crore.

The promoters holding in the company stood at 74.60%, while institutions and non-institutions held 0.91% and 24.49% respectively.

Panacea Biotec has received the Certificate of GMP Compliance from State Service of Ukraine on Medicines and Drugs Control with Manufacturing Authorization for 22 medicinal products, including 4 oncology products for a period valid till June 24, 2020. Under this Manufacturing Authorization the company’s oral solid dosage manufacturing facility and oncology facility at Baddi, Himachal Pradesh have been certified as complying with the Good Manufacturing Practices.

The 22 products under approval are in various therapeutic categories including organ transplantation, diabetes management, oncology, piles management, pain management and gastroenterology etc. Both the oral solid dosage manufacturing facility and oncology facility were inspected by the auditors from State Services of Ukraine on Medicines and Drug Control during the period from June 19, 2017 to June 24, 2017.

Panacea Biotec is a leading biotechnology company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and leading Biotechnology Companies in India.

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×